Serabelisib is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Serabelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Serabelisib overview

Serabelisib (TAK-117, INK1117) is under development for solid tumors, metastatic triple negative breast cancer, squamous Cell Carcinoma, transitional cell carcinoma, adenocarcinoma of colon and rectum, endometrial cancer, ovarian cancer, endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, mucinous adenocarcinoma, carcinosarcoma and endometrial carcinoma. It is administered through oral route in the form of capsule and tablet. It acts by targeting the PI3Kalpha isoform. It was under development for the treatment of advanced solid tumor malignancies including squamous non-small cell lung cancer, relapsed and refractory gastric cancer, metastatic clear cell renal cell carcinoma and adenocarcinoma of the gastroesophageal junction.

Millennium Pharmaceuticals overview

Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Serabelisib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.